{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:22:21Z","timestamp":1787606541067,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e31924","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T19:45:13Z","timestamp":1716579913000},"page":"e31924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Analysis of the pharmacokinetics and efficacy of RBD1016 \u2013 A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK\/PD model"],"prefix":"10.1016","volume":"10","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taohua","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Svedlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Charlotte","family":"Egnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.heliyon.2024.e31924_bib1","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1093\/nar\/gkaa576","article-title":"A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics","volume":"48","author":"Deprey","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"6669","key":"10.1016\/j.heliyon.2024.e31924_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"7006","key":"10.1016\/j.heliyon.2024.e31924_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature02872","article-title":"Revealing the world of RNA interference","volume":"431","author":"Mello","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","article-title":"RNA-based therapeutics: current progress and future prospects","volume":"19","author":"Burnett","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e31924_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e31924_bib6","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1021\/acsomega.1c01755","article-title":"Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation","volume":"6","author":"Cui","year":"2021","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e31924_bib7","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1093\/nar\/gkaa125","article-title":"Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonuclease","volume":"48","author":"Kumar","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.heliyon.2024.e31924_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.omtn.2022.06.011","article-title":"Delivery of therapeutic small interfering RNA: the current patent-based landscape","volume":"29","author":"Chen","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e31924_bib9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31924_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/jpet.122.001229","article-title":"Plasma and liver pharmacokinetics of the N-acetylgalactosamine short interfering RNA JNJ-73763989 in recombinant adeno-associated-hepatitis B virus-infected mice","volume":"383","author":"Sandra","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31924_bib13","first-page":"871","article-title":"Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection","volume":"2","author":"Sarvari","year":"2011","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31924_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179605","article-title":"Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo","volume":"12","author":"Cheng","year":"2017","journal-title":"PLoS One"},{"issue":"Pt 1","key":"10.1016\/j.heliyon.2024.e31924_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1099\/vir.0.004408-0","article-title":"Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro","volume":"90","author":"Starkey","year":"2009","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib16","first-page":"1469","article-title":"Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses","volume":"45","author":"Trubetskoy","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e31924_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpdd.318","article-title":"Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers","volume":"6","author":"Schluep","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221093856","article-title":"JNJ-73763989 pharmacokinetics and safety: liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B","volume":"27","author":"Gane","year":"2022","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/pharmaceutics13010092","article-title":"Pharmacokinetic-pharmacodynamic modeling of tumor targeted drug delivery using nano-engineered mesenchymal stem cells","volume":"13","author":"Cheng","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e31924_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/psp4.12706","article-title":"Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making-A workshop summary","volume":"10","author":"Jean","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e31924_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-022-03333-8","article-title":"Pharmacokinetic and pharmacodynamic modeling of siRNA therapeutics - a minireview","author":"Jeon","year":"2022","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e31924_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.121.000805","article-title":"Minimal physiologically based pharmacokinetic-pharmacodynamic (mPBPK-PD) model of N-Acetylgalactosamine-Conjugated small interfering RNA disposition and gene silencing in preclinical species and humans","volume":"379","author":"Ayyar","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.heliyon.2024.e31924_bib25","unstructured":"FDA. Givosiran Multi-Discipline Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212194Orig1s000MultidisciplineR.pdf."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e31924_bib26","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/19420862.2017.1373924","article-title":"Capacity limits of asialoglycoprotein receptor-mediated liver targeting","volume":"9","author":"Bon","year":"2017","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31924_bib27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/01926233221088283","article-title":"Organ weights in relation to age and sex in cynomolgus monkeys (Macaca fascicularis)","volume":"50","author":"Amato","year":"2022","journal-title":"Toxicol. Pathol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","article-title":"Strategies for silencing human disease using RNA interference","volume":"8","author":"Kim","year":"2007","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib29","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1038\/s41467-021-23250-5","article-title":"Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs","volume":"12","author":"Xue","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31924_bib30","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-Acetylgalactosamine-Conjugated small interfering RNA are highly predictable and build confidence in translation to human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e31924_bib31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cpt.1363","article-title":"Model-informed drug development: current US regulatory practice and future considerations","volume":"105","author":"Wang","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e31924_bib32","doi-asserted-by":"crossref","unstructured":"Ranasinghe P, Addison ML, Dear JW, Webb DJ. Small interfering RNA: discovery, pharmacology and clinical development-An introductory review. Br. J. Pharmacol.. doi:10.1111\/bph.15972.","DOI":"10.1111\/bph.15972"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e31924_bib33","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e31924_bib34","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1093\/nar\/gkac456","article-title":"Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics","volume":"50","author":"Humphreys","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e31924_bib35","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib36","first-page":"25","article-title":"Animal models for the study of hepatitis B virus infection","volume":"39","author":"Guo","year":"2018","journal-title":"Zool. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31924_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","article-title":"Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression","volume":"26","author":"Willoughby","year":"2018","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e31924_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10616-011-9407-0","article-title":"A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development","volume":"64","author":"Severgnini","year":"2012","journal-title":"Cytotechnology"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e31924_bib40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31924_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/nat.2019.0841","article-title":"Population pharmacokinetic-pharmacodynamic model of serum transthyretin following patisiran administration","volume":"30","author":"Goel","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31924_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/nat.2022.0010","article-title":"Cross-species translation of biophase half-life and potency of GalNAc-conjugated siRNAs","volume":"32","author":"Boianelli","year":"2022","journal-title":"Nucleic Acid Therapeut."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e31924_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112754","article-title":"Review of the existing translational pharmacokinetics modeling approaches specific to monoclonal antibodies (mAbs) to support the first-in-human (FIH) dose selection","volume":"23","author":"Pasquiers","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e31924_bib44","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/17425255.2014.934671","article-title":"The application of allometric scaling principles to predict pharmacokinetic parameters across species","volume":"10","author":"Huang","year":"2014","journal-title":"Expet Opin. Drug Metabol. Toxicol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024079556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024079556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:48:19Z","timestamp":1787604499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024079556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024079556"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31924","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the pharmacokinetics and efficacy of RBD1016 \u2013 A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK\/PD model","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e31924"}}